US · SGRY · MEDICAL - CARE FACILITIES
Surgery Partners, Inc. (SGRY) intrinsic value and stock valuation
$26.78as of 2026-11-21 · Mkt cap 2.03B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Surgery Partners, Inc. DCF and intrinsic value
InvestorsCraft values SGRY with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from SGRY’s statements →
Surgery Partners, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.31B | $3.11B | $2.74B | $2.54B | $2.23B |
| Operating income | $389.5M | $348.8M | $328M | $345.2M | $302.2M |
| Net income | -$-77.9M | -$-168.1M | -$-11.9M | -$-54.6M | -$-70.9M |
| EPSd | -$-612.37K | -$-1.33M | -$-94.74K | -$-593.8K | -$-978.88K |
| Operating cash flow | $274.3M | $300.1M | $293.8M | $158.8M | $87.1M |
| Capital expenditure | -$-78.7M | -$-90.4M | -$-88.8M | -$-80.6M | -$-57.6M |
| Free cash flow | $195.6M | $209.7M | $205M | $78.2M | $29.5M |
| Total assets | $8.24B | $7.89B | $6.88B | $6.68B | $6.12B |
| Total debt | $4.02B | $3.7B | $3.06B | $2.93B | $3.29B |
| Net debt | $3.78B | $3.43B | $2.87B | $2.65B | $2.9B |
| Total equity | $3.53B | $3.64B | $3.36B | $3.28B | $2.3B |
| Cash and short-term investments | $239.9M | $269.5M | $195.9M | $282.9M | $389.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.31B | $3.11B | $2.74B | $2.54B | $2.23B |
| Cost of revenue | $2.54B | $2.37B | $2.1B | $1.96B | $1.73B |
| Gross profit | $765M | $745.6M | $647.5M | $574.9M | $491.4M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $522.7M | $138.7M | $120.9M | $102.2M | $104M |
| Other expenses | -$-147.2M | $258.1M | $198.6M | $127.5M | $85.2M |
| Operating expenses | $375.5M | $396.8M | $319.5M | $229.7M | $189.2M |
| Cost and expenses | $2.92B | $2.77B | $2.42B | $2.19B | $1.92B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $272.6M | $201.7M | $193M | $234.9M | $221M |
| Depreciation and amortization | $176M | $152.6M | $118.1M | $114.8M | $98.8M |
| Ebitda | $565.5M | $501.4M | $446.1M | $460M | $401M |
| Operating income | $389.5M | $348.8M | $328M | $345.2M | $302.2M |
| Total other income/expenses, net | -$-272.6M | -$-201.7M | -$-193M | -$-234.9M | -$-221M |
| Income before tax | $116.9M | $147.1M | $135M | $110.3M | $81.2M |
| Income tax expense | $18M | $134.6M | -$-300K | $23.3M | $10.5M |
| Net income | -$-77.9M | -$-168.1M | -$-11.9M | -$-54.6M | -$-70.9M |
| Weighted average shares outstanding | $127.2M | $126.1M | $125.6M | $92M | $72.4M |
| Weighted average diluted shares outstanding | $127.2M | $126.1M | $125.6M | $92M | $72.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $239.9M | $269.5M | $195.9M | $282.9M | $389.9M |
| Net receivables | $602.2M | $579.1M | $496.4M | $456.3M | $430.2M |
| Inventory | $96.6M | $88.4M | $75.2M | $71.4M | $61.1M |
| Total current assets | $1.15B | $1.12B | $895M | $921M | $946.1M |
| Property, plant and equipment, net | $1.44B | $1.38B | $1.22B | $1.16B | $953.8M |
| Goodwill and intangible assets | $5.24B | $5.11B | $4.38B | $4.18B | $3.96B |
| Long-term investments | $234M | $215.4M | $184.1M | $190.3M | $88.7M |
| Total non-current assets | $7.09B | $6.77B | $5.98B | $5.76B | $5.17B |
| Total assets | $8.24B | $7.89B | $6.88B | $6.68B | $6.12B |
| Accounts payable | $208.7M | $208.7M | $171.8M | $151.6M | $124.9M |
| Short-term debt | $142M | $142.4M | $110.9M | $99.3M | $100.5M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $3.2M | $64.4M |
| Total current liabilities | $615.5M | $624.4M | $523M | $493.4M | $536.8M |
| Long-term debt | $3.88B | $3.56B | $2.95B | $2.83B | $3.19B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $4.1B | $3.63B | $2.99B | $2.91B | $3.28B |
| Capital lease obligations | $1.22B | $333.1M | $286.5M | $307.9M | $355.7M |
| Total liabilities | $4.72B | $4.25B | $3.51B | $3.4B | $3.82B |
| Common stock | $1.3M | $1.3M | $1.3M | $1.3M | $900K |
| Retained earnings | -$-815.2M | -$-737.3M | -$-569.2M | -$-557.3M | -$-502.7M |
| Accumulated other comprehensive income (loss) | -$-13.8M | $4.8M | $57.5M | $76.2M | -$-31.5M |
| Total equity | $3.53B | $3.64B | $3.36B | $3.28B | $2.3B |
| Total investments | $234M | $215.4M | $184.1M | $190.3M | $88.7M |
| Total debt | $4.02B | $3.7B | $3.06B | $2.93B | $3.29B |
| Net debt | $3.78B | $3.43B | $2.87B | $2.65B | $2.9B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $98.9M | $12.5M | $135.3M | $87M | $70.7M |
| Depreciation and amortization | $176M | $152.6M | $118.1M | $114.8M | $98.8M |
| Stock-based compensation | $14.8M | $33.3M | $17.7M | $18.4M | $17.4M |
| Change in working capital | -$-110.4M | -$-118.9M | -$-62.3M | -$-102.3M | -$-149.1M |
| Accounts receivable | -$-53.8M | -$-72.1M | -$-47.2M | -$-35.3M | -$-32.1M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $274.3M | $300.1M | $293.8M | $158.8M | $87.1M |
| Investments in property, plant and equipment | -$-78.7M | -$-90.4M | -$-88.8M | -$-80.6M | -$-57.6M |
| Acquisitions, net | -$-162.1M | -$-378.8M | -$-128.9M | -$-228.7M | -$-280.4M |
| Net cash used for investing activities | -$-246.6M | -$-488.5M | -$-225.6M | -$-307.9M | -$-331.7M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $882.9M | $581.8M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | -$-5.1M |
| Net cash used for financing activities | -$-57.3M | $262M | -$-155.2M | $42.1M | $316.3M |
| Net change in cash | -$-29.6M | $73.6M | -$-87M | -$-107M | $71.7M |
| Cash at end of period | $239.9M | $269.5M | $195.9M | $282.9M | $389.9M |
| Operating cash flow | $274.3M | $300.1M | $293.8M | $158.8M | $87.1M |
| Capital expenditure | -$-78.7M | -$-90.4M | -$-88.8M | -$-80.6M | -$-57.6M |
| Free cash flow | $195.6M | $209.7M | $205M | $78.2M | $29.5M |
Line items
Line items
Line items
About Surgery Partners, Inc.
Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services. These surgical venues include both ambulatory surgery centers and dedicated surgical hospitals, delivering non-urgent surgical procedures across various specialties such as gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The surgical hospitals additionally offer comprehensive ancillary services, including diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care. The dedicated Ancillary Services segment further encompasses multi-specialty physician practices, urgent care facilities, and anesthesia services. By December 31, 2021, the company's portfolio consisted of 126 surgical facilities—specifically, 108 ambulatory surgical centers and 18 surgical hospitals—situated across 31 states. Founded in 2004, Surgery Partners, Inc. maintains its headquarters in Brentwood, Tennessee.
- CEO
- J. Eric Evans
- Employees
- 16K
- Beta
- 1.89
Explore
Frequently asked questions
What is the intrinsic value of Surgery Partners, Inc. (SGRY)?
Surgery Partners, Inc. (SGRY) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SGRY undervalued?
SGRY trades at a price of $26.78 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.